Fibromyalgia syndrome

Journal of Rheumatology

Volumn 32, Issue 11, 2005, Pages 2270-2277

  Mease, Philip J ^a,b,r   Clauw, Daniel J ^c,d,e   Arnold, Lesley M ^f,g   Goldenberg, Don L ^h   Witter, James ^f   Williams, David A ^e,i,j   Simon, Lee S ^k   Strand, C Vibeke ^l   Bramson, Candace ^m   Martin, Susan ^m   Wright, Timothy M ⁿ   Littman, Bruce ^m   Wernicke, J F ^o   Gendreau, R Michael ^p   Crofford, Leslie J ^f,q  

^a Swedish Hospital Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Division of Rheumatology   (Puerto Rico)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f Department of Psychiatry ^*

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Medicine/Rheumatology

^j Research Development

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l STANFORD UNIVERSITY   (United States)

^m PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

ⁿ Novartis Institutes for BioMedical Research   (Switzerland)

^o ELI LILLY AND COMPANY   (United States)

^p Cypress Bioscience Inc   (United States)

^q UNIVERSITY OF KENTUCKY   (United States)

^r Seattle Rhumatology Associates   (United States)

more..

Author keywords

Chronic pain; Fibromyalgia; OMERACT; Outcome measures

Indexed keywords

DULOXETINE; FLUOXETINE; HUMAN GROWTH HORMONE; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; PARACETAMOL; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR THERAPY; CHRONIC DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE THERAPY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FIBROMYALGIA; FUNCTIONAL ASSESSMENT; HUMAN; META ANALYSIS; MUSCLE WEAKNESS; OUTCOMES RESEARCH; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SLEEP; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

DELPHI TECHNIQUE; FIBROMYALGIA; HUMANS; QUALITY OF HEALTH CARE; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 27744590935     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
3. Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002;28:181-99.
4. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701.
5. 4a. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment, J Rheumatol 2005;32 Suppl 75:6-21.
6. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999;74:385-98.
7. Barkhuizen A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002;28:261-90.
8. Busch A, Schachter C, Peloso P, Bombardier C. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2002;CD003786.
9. Burckhardt CS, Bjelle A. Education programmes for fibromyalgia patients: description and evaluation. Baillieres Clin Rheumatol 1994;8:935-55.
10. Burckhardt CS, Mannerkorpi K, Hedenberg L, Bjelle A. A randomized, controlled clinical trial of education and physical training for women with fibromyalgia. J Rheumatol 1994;21:714-20.
11. Williams DA. Psychological and behavioural therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:649-65.
12. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003;48:2916-22.
13. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106:337-45.
14. Turk DC, Dworkin RH. What should be the core outcomes in chronic pain clinical trials? Arthritis Res Ther 2004;6:151-4.
15. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-33.
16. Wolfe F, Hawley DJ, Goldenberg DL, Russell IJ, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J Rheumatol 2000;27:1989-99.
17. Iverson M. The Fibromyalgia Impact Questionnaire. Arthritis Care Res 2003;49:S210-S213.
18. Henriksson CM. Longterm effects of fibromyalgia on everyday life. A study of 56 patients. Scand J Rheumatol 1994;23:36-41.
19. Gendreau M, Hufford MR, Stone AA. Measuring clinical pain in chronic widespread pain: selected methodological issues. Best Pract Res Clin Rheumatol 2003;17:575-92.
20. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-13.
21. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84.
22. Wernicke JF, Rosen AS, Lu Y, et al. Duloxitene in the treatment of fibromyalgia. Arthritis Rheum 2004;50:S697.
23. Crofford LJ, Rowbotham MC, Mease PJ. et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73.
24. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45.
25. Gendreau M, Mease P, Rao S, Kranzler J, Clauw D. Milnacipran: A potential new treatment of fibromyalgia [abstract]. Arthritis Rheum 2003;48 Suppl:S617.
26. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31.
27. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
28. Cleeland C. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
29. Martinez-Lavin M, Lopez S, Medina M, Nava A. Use of the Leeds Assessment of Neuropathic Symptoms and Signs Questionnaire in patients with fibromyalgia. Semin Arthritis Rheum 2003;32:407-11.
30. Gracely RH, Grant MA, Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003;17:593-609.
31. Sinclair D, Starz T, Turk D. The Manual Tender Point Survey. [Internet] [Accessed July 14, 2005]. Available from National Fibromyalgia Association: http://fmaware.org/doctor/tenderpt.htm
32. Littlejohn G. A database for fibromyalgia. [Internet] 1993 [accessed July 14, 2005]. Available from Medical Pain Education:http://websites.golden-orb. com/pain-education/100130.php.
33. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993;42:93-9.
34. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
35. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
36. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3.
37. Hays R, Stewart A. Measuring functioning and well-being. In: Stewart A, Ware J, editors. Sleep measures. Durham, NC: Duke University Press; 1992:232-59.
38. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
39. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40.
40. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-7.
41. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
42. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70.
43. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
44. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33; quiz 34-57.
45. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, version 2.0, 4/97 revision). New York: Biometrics Research Department, New York State Psychiatric Institute; 1997.
46. Turk DC, Monarch ES, Williams AD. Psychological evaluation of patients diagnosed with fibromyalgia syndrome: a comprehensive approach. Rheum Dis Clin North Am 2002;28:219-33.
47. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
48. Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-91.
49. Simms RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991;18:1558-63.
50. Jones J, Duncan H. Qualitative research: consensus methods for medical and health services research. BMJ 1995;311:376-80.
51. Linstone HA. The Delphi Technique. In: Fowles J, editor. Handbook of futures research. Westport, CT; London, England: Greenwood Press; 1978:273-300.
52. Oranga H, Nordberg E. The Delphi panel method for generating health information. Health Policy Planning 1993;8:405-12.
53. Pill J, The Delphi method: substance, context, a critique and an annotated bibliography. Socio-Econ Plan Sci 1971;5:57-71.
54. Rowe G, Wright G, Bolger F. Delphi. A reevaluation of research and theory. Technological Forecasting and Social Change 1991;39:235-51.
55. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7.
56. Russell I, Kamin M, Bennett RM, et al. Efficacy in tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7.
57. Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1998.
58. Bennett RM. Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol 1998;57 Suppl 2:72-6.
59. Donta ST, Clauw DJ, Engel CG Jr, et al. Cognitive behavioral therapy and aerobic exercise for Gulf War veterans' illnesses: a randomized controlled trial. JAMA 2003;289:1396-404.
60. Williams DA, Cary MA, Groner KH, et al. Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol 2002;29:1280-6.
61. Center for Drug Evaluation and Research. CDER 2003 Meeting Documents: Arthritis Advisory Committee. June 23, 2003 [Internet. Accessed July 14, 2005] Available from CDER website: http://www.fda.gov/ohrms/dockets/ac/cder03. html#Arthritis